AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$42.57 USD
-0.06 (-0.14%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $42.57 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.57 USD
-0.06 (-0.14%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $42.57 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Elevance Health, Inc. (ELV) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Elevance Health (ELV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's How Much a $1000 Investment in AMN Healthcare Services Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
AMN Healthcare (AMN) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
AMN Healthcare (AMN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
AMN Healthcare Services (AMN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed at $120.04 in the latest trading session, marking a +1.59% move from the prior day.
Philips' (PHG) Q3 Earnings Down on Supply Chain Constraints
by Zacks Equity Research
Koninklijke Philips' (PHG) Q3 top and bottom-line results reflect the negative impact of supply chain constraints, COVID lockdowns in China and the Russia-Ukraine war.
Are Investors Undervaluing AMN Healthcare Services (AMN) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Abiomed's (ABMD) Latest Impella Offering Approved by the FDA
by Zacks Equity Research
Abiomed's (ABMD) latest regulatory clearance for the Impella Low Profile Sheath is expected to improve patient outcomes.
Veeva Systems' (VEEV) New Launch to Streamline Clinical Data
by Zacks Equity Research
Veeva Systems' (VEEV) new offering is expected to speed up the aggregation and cleaning of clinical trial data, thereby making it usable.
Buy These 4 Low-Beta Stocks to Combat Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Scorpio Tankers Inc. (STNG), AMN Healthcare (AMN), Ardmore (ASC) and Lancaster (LANC) are poised to gain.
Intuitive Surgical (ISRG) Q3 Earnings Beat, Procedures Recover
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results reflect health demand for procedures, partially offset by lower system sales and unfavorable currency.
Veeva Systems' (VEEV) New Launch to Enhance Digital Trials
by Zacks Equity Research
Veeva Systems' (VEEV) new offering is expected to meet the requirements of patients, sites and sponsors, thereby streamlining trial activities.
BD (BDX)-Biocorp's Latest Deal to Enhance Tracking Adherence
by Zacks Equity Research
BD's (BDX) newest agreement is expected to enable the care provision to transition to alternate settings and improve chronic disease outcomes.
3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.
Reasons to Retain West Pharmaceutical (WST) in Your Portfolio
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
3 Reasons to Add Inogen (INGN) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
Nevro (NVRO) Gains Following FDA Approval for Senza HFX iQ
by Zacks Equity Research
Nevro (NVRO) gets FDA approval for its next-generation SCS system, Senza HFX iQ, for treating chronic back and leg pain.
Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
AMN vs. DOCS: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMN vs. DOCS: Which Stock Is the Better Value Option?
Accuray's (ARAY) New Treatment Package to Boost Patient Outcome
by Zacks Equity Research
Accuray's (ARAY) latest automated breast cancer treatment package for the Radixact System is expected to extend and improve the quality of patients' lives.
AMN Healthcare Services (AMN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed the most recent trading day at $113.46, moving +1.53% from the previous trading session.
QuidelOrtho (QDEL) Reports Solid Preliminary Q3 Revenues
by Zacks Equity Research
QuidelOrtho's (QDEL) revenue growth in the third quarter is likely to have been boosted by continued strength in its non-COVID-19 product sales.
3 Medical Stocks to Buy in 2022 for Long-Term Resilience
by Indrajit Bandyopadhyay
Here we discuss two Medical companies, VRTX, ISRG and AMN, that may prove to be wealth creators for investors over the long term on the back of their strong fundamentals.
AMN Healthcare Services (AMN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed at $111.75 in the latest trading session, marking a -1.51% move from the prior day.
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.
Thermo Fisher (TMO) Launches New TaqPath Panel in Europe
by Zacks Equity Research
This panel of Thermo Fisher (TMO), apart from detecting GI bacteria, also helps in identifying the root cause of an infection and administering the best suitable treatment fast.